Kwality Pharmaceuticals Ltd

Quality Pharmaceuticals Limited informed the BSE Limited that the trading window for dealing in equity shares of the company will be closed for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026.

Kwality Pharmaceuticals Limited announced that its members approved the regularization of Swanith Kapoor as a Non-Executive Independent Director for a term of five consecutive years, effective June 2, 2026, to June 1, 2031, and the reappointment of Aditya Arora as Whole Time Director for a period of five years, effective September 30, 2026, to September 29, 2031.

Kwality Pharmaceuticals Ltd share price softened by 1.64% to Rs 2609.05. The Company's net profit inched up 1.22% to Rs 25.62 crore, while revenue from operations slightly gained 3.34% to Rs 162.35 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.54 lakh crore, gaining 5.14%. It has marginally improved by 0.74% over last one week and climbed by 13.39% in last one month while the market capitalization of Kwality Pharmaceuticals Ltd has improved by 2.06% and 55.70% in the same period respectively. Profit before tax (PBT) of Kwality Pharmaceuticals Ltd stood at Rs 33.99 crore in Q2 FY26, jumping 99.59% year-on-year, and rising 7.33% quarter-on-quarter. EBITDA came in at Rs 40 crore, expanding by 69.78% YoY and easing 7.14% sequentially. Total expenses grew marginally by 2.19% to Rs 126.33 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 85.34 crore, inching up 7.10% YoY, while employee benefits expense was at Rs 14.74 crore, ticking higher by 3.66% YoY. For the TTM ended FY26, revenue from operations jumped by 20.52% to Rs 370.2 crore, while net profit soared by 68.50% to Rs 39.8 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 6221% to Rs 78.47 crore, and PBT witnessed a strong rise of 74.08% to Rs 54.14 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 52.72 crore in FY26, as against Rs 42.98 crore in FY25. Kwality Pharmaceuticals Ltd surged by 137.66% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.63% during the same period.

Kwality Pharmaceuticals Limited announced that its board approved the re-appointment of Aditya Arora as a Whole Time Director for a further five-year period, commencing September 30, 2026, and subject to shareholder approval at the company’s 43rd Annual General Meeting. The board also approved the regularization of Swanith Kapoor as an Independent Director and appointed M/s Verma Khushwinder & Co. as Cost Auditors for the financial year 2026-27, with remuneration subject to ratification by shareholders. The company will hold its 43rd Annual General Meeting on August 31, 2026, via video conferencing, and e-voting will be available from August 28 to August 30, 2026.

Kwality Pharmaceuticals has achieved a significant milestone in its biologics development journey after receiving permission from the Central Drugs Standard Control Organization (CDSCO) to manufacture pilot batches of Pembroluzimab for preclinical studies. The approval follows a comprehensive review of the product's development data submitted by the Company's R&D team. Based on the data evaluated, CDSCO has granted permission to proceed with pilot-scale manufacturing for the generation of preclinical batches, marking the product's transition from the research and development stage to Pre-Clinical stage.

The company's consolidated net profit surged 74.60% to Rs 25.30 crore in Q4 FY26, compared with Rs 14.49 crore in the same period last year. Revenue from operations rose 35.81% YoY to Rs 157.11 crore in the quarter ended 31 March 2026. On a sequential basis, net profit increased 58.02% and revenue grew 27.27% over Q3 FY26. Profit before tax stood at Rs 31.67 crore in Q4 FY26, up 66.07% year-on-year and up 36.68% quarter-on-quarter. EBITDA jumped 50.38% to Rs 38.8 crore in the March quarter, compared with Rs 25.8 crore a year earlier. EBITDA margin improved to 24.6% from 22% in the corresponding period last year. For the full financial year FY26, the company reported a 69% surge in consolidated net profit to Rs 67.35 crore, while revenue from operations rose 35.89% to Rs 503.08 crore. Kwality Pharmaceuticals is engaged in the business of manufacturing & trading in pharmaceuticals & allied products. Powered by Capital Market - Live

Net profit of Kwality Pharmaceuticals rose 74.60% to Rs 25.30 crore in the quarter ended March 2026 as against Rs 14.49 crore during the previous quarter ended March 2025. Sales rose 35.81% to Rs 157.11 crore in the quarter ended March 2026 as against Rs 115.68 crore during the previous quarter ended March 2025. For the full year,net profit rose 69.01% to Rs 67.35 crore in the year ended March 2026 as against Rs 39.85 crore during the previous year ended March 2025. Sales rose 35.89% to Rs 503.08 crore in the year ended March 2026 as against Rs 370.20 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales157.11115.68 36 503.08370.20 36 OPM %24.6722.37 -23.5021.72 - PBDT36.9324.16 53 110.1372.43 52 PBT31.6719.07 66 90.3254.14 67 NP25.3014.49 75 67.3539.85 69 Powered by Capital Market - Live

Kwality Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 19 May 2026.

Kwality Pharmaceuticals has received upgrade in credit ratings for bank loan facilities of the company at ICRA BBB+; Stable / ICRA A2. Further, the ratings have been removed from the 'Issuer Not Cooperating' category.

Net profit of Kwality Pharmaceuticals rose 87.69% to Rs 16.01 crore in the quarter ended December 2025 as against Rs 8.53 crore during the previous quarter ended December 2024. Sales rose 46.24% to Rs 123.44 crore in the quarter ended December 2025 as against Rs 84.41 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales123.4484.41 46 OPM %24.2620.73 - PBDT28.0015.95 76 PBT23.1811.39 104 NP16.018.53 88 Powered by Capital Market - Live